about
Methadone for chronic non-cancer pain in adultsMethadone for chronic non-cancer pain in adultsSingle dose intravenous paracetamol or intravenous propacetamol for postoperative painPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysisProliposomal Ropivacaine Oil: Pharmacokinetic and Pharmacodynamic Data After Subcutaneous Administration in Volunteers.Neuropathic pain: an updated grading system for research and clinical practice.Topical NSAID therapy for musculoskeletal pain.Structural and functional characterization of nerve fibres in polyneuropathy and healthy subjects.The challenge of pain management in patients with myasthenia gravis.Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies.The neuropathic component in persistent postsurgical pain: a systematic literature review.A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain.Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting.Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study.Enhanced antinociceptive efficacy of epidural compared with i.v. methadone in a rat model of thermal nociception.Neuropathic Pain: Central vs. Peripheral Mechanisms.Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain.A Novel Proliposomal Ropivacaine Oil: Pharmacokinetic-Pharmacodynamic Studies After Subcutaneous Administration in Pigs.High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans.Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study.[Caffeine as adjuvant analgeticum for treating acute pain].Development and validation of shortened, restructured Treatment Outcomes in Pain Survey instrument (the S-TOPS) for assessment of individual pain patients' health-related quality of life.Do Changes in Sensory Processing Precede Low Back Pain Development in Healthy Individuals?The suprasacral parallel shift vs lumbar plexus blockade with ultrasound guidance in healthy volunteers--a randomised controlled trial.Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy.Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial.Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model.How central is central post-stroke pain? The role of afferent input in post-stroke neuropathic pain: a prospective open-label pilot study.Phantom limb pain: treatment strategies.The sodium-channel blocker lidocaine in subanesthetic concentrations reduces spontaneous and evoked pain in human painful neuromaTopical Capsaicin Response as a Phenotypic Measure in Patients with PainPhantom Limb PainIntravenous patient-controlled analgesia for acute postoperative painAAPT Diagnostic Criteria for Peripheral Neuropathic Pain: Focal and Segmental DisordersAngiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit PainAdverse event assessment and reporting in clinical trials of cannabinoids for chronic pain: Protocol for a Systematic Review (Preprint)Assessment and reporting of safety outcomes in clinical trials of cannabinoids for chronic pain: Protocol for a Systematic Review (Preprint)Somatosensory phenotyping for better translation in neuropathic pain?Neuropathic Pain Following Surgery
P50
Q24202968-425EA28A-E84B-440E-A497-32FD7DBA94B9Q24240848-F2B9E60C-F9D6-4B22-9652-9E61BFFBE3ECQ26471934-9488AAD5-AA31-48FB-BC34-C1D152D93DEBQ28085455-F3F40DAB-6F77-455A-A980-EED215427CFBQ31071860-60413AC1-B36D-4C76-BC6E-A160E0FC49DCQ34523633-33E129DA-7CC3-46D0-9F8C-F0B191C52B78Q34617511-74566AAB-A55A-4EA9-B374-0DEFCB3894D4Q36329566-53A60F8F-4571-4954-B9CB-F17964E4FB0BQ37577775-117DCF10-96AC-4F67-94C9-EB6E0B347610Q37780763-AC11FF38-FC26-4E19-8DF0-E75A41F9B7C9Q38070200-EC78705D-B4CB-4F2F-8F32-0F4DABD7D712Q38233751-8833044D-08CB-42D2-AEE6-AB895EFC3CF4Q38488102-CC04A5F4-5318-4708-AACD-2AA460047153Q38827493-45073AB8-B97F-4BE1-BDDB-EF521A6AC8D2Q39176501-055FA0B3-5A35-4702-9598-9D123BF4215FQ39224108-B50FEFAA-0A39-411D-B2FE-E3AECA0198E0Q39255819-6484D14E-07C2-4BA0-9294-5248EC47DE18Q39311223-0819F26C-6ECD-4983-8430-A51D3A314BCCQ41602253-D6E514DB-A26D-4318-8616-3FD48E5964D1Q42654914-271180C0-DD53-43A1-8915-803A0692218DQ43272818-1874ED40-7CD4-493F-AF4A-27DA0D02FF35Q44142542-5EB7D658-4EA7-4ABB-9E73-C88E9013CED5Q45989582-C1C0BC8E-DE57-46B8-9516-9067F2314D5AQ47744295-2A0ACC3D-8175-4466-8D29-5BD8B8B4E41BQ47850869-D4B2BFD1-D3E2-407F-AEE6-43A6925E3538Q47888219-25706068-A893-4564-A684-57B446D44395Q49644160-798DCFA5-4008-4A76-A060-38C4B2E8F61BQ53794671-1DA48C98-4AFE-4856-A0CD-204CC5921150Q53835533-D0C86176-4A9A-4A04-A728-9BFC909C7FCBQ54283635-14D38BAA-5E93-43B1-A6B7-A6539075DD7CQ60678712-4CE68587-1757-4F0A-AB03-5C9634F5CC60Q60678713-536EC50F-7C87-4C21-A551-4E4615A25B95Q60681406-951998FF-F683-4808-A0F8-C257F06A0081Q60681408-D6303F56-5C6E-4E07-BAC8-A62FBB70E8F2Q60682867-45477364-E4F3-4BE2-9170-A3EA40BB7FD0Q60682871-7CDAC510-1F55-4E89-ADCC-A87E6D45A070Q60682873-498E178A-37C2-4890-A036-1DD04779BCDDQ60682875-C685473C-F391-42B5-B019-977E65D249D1Q60682883-0D95A4C7-DFF8-493E-8B33-916A882DAC71Q60682888-C8E3CB9A-F93D-40E7-A52C-9A6D28A39513
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Simon Haroutounian
@ast
Simon Haroutounian
@en
Simon Haroutounian
@en-gb
Simon Haroutounian
@es
Simon Haroutounian
@nl
Simon Haroutounian
@sl
type
label
Simon Haroutounian
@ast
Simon Haroutounian
@en
Simon Haroutounian
@en-gb
Simon Haroutounian
@es
Simon Haroutounian
@nl
Simon Haroutounian
@sl
prefLabel
Simon Haroutounian
@ast
Simon Haroutounian
@en
Simon Haroutounian
@en-gb
Simon Haroutounian
@es
Simon Haroutounian
@nl
Simon Haroutounian
@sl
P106
P1153
18434186300
P21
P31
P496
0000-0003-2231-5452